Naoto Sugeno

Dr. Naoto Sugeno


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in Neurobiology of Disease
Verified
Journal Article
Closed access
EMEmiko Miura
Emiko Miura
Takafumi HasegawaTakafumi Hasegawa
Takafumi Hasegawa
MKMasatoshi Konno
Masatoshi Konno
Mari SuzukiMari Suzuki
Mari Suzuki
NSNaoto Sugeno
Naoto Sugeno
MAMasashi Aoki
Masashi Aoki

14 August 2012 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
MKMasatoshi Konno
Masatoshi Konno
Takafumi HasegawaTakafumi Hasegawa
Takafumi Hasegawa
TBToru Baba
Toru Baba
EMEmiko Miura
Emiko Miura
NSNaoto Sugeno
Naoto Sugeno
ATAtsushi Takeda
Atsushi Takeda
Background: The intracellular deposition of misfolded proteins is a common neuropathological hallmark of most neurodegenerative disorders. Increasing evidence suggests that these pathogenic proteins may spread to neighboring cells and induce the propagation of neurodegeneration. Results: In this study, we have demonstrated that α-synuclein (αSYN), a major constituent of intracellular inclusions in synucleinopathies, was taken up by neuronal and oligodendroglial cells in both a time- and concentration-dependent manner. Once incorporated, the extracellular αSYN was immediately assembled into high-molecular-weight oligomers and subsequently formed cytoplasmic inclusion bodies. Furthermore, αSYN uptake by neurons and cells of the oligodendroglial lineage was markedly decreased by the genetic suppression and pharmacological inhibition of the dynamin GTPases, suggesting the involvement of the endocytic pathway in this process. Conclusions: Our findings shed light on the mode of αSYN uptake by neuronal and oligodendroglial cells and identify therapeutic strategies aimed at reducing the propagation of protein misfolding.

15 February 2010 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
ATAtsushi Takeda
Atsushi Takeda
NSNaohiro Saito
Naohiro Saito
TBToru Baba
Toru Baba
AKAkio Kikuchi
Akio Kikuchi
NSNaoto Sugeno
Naoto Sugeno
YIYasuto Itoyama
Yasuto Itoyama

1 January 2017 in The Tohoku Journal of Experimental Medicine
Verified
Journal Article
Closed access
THTakafumi Hasegawa
Takafumi Hasegawa
NSNaoto Sugeno
Naoto Sugeno
AKAkio Kikuchi
Akio Kikuchi
TBToru Baba
Toru Baba
MAMasashi Aoki
Masashi Aoki
Parkinson's disease (PD) is the second most common neurodegenerative disorder that is characterized by progressive movement disability and a variety of non-motor symptoms. The neuropathology of PD consists of the loss of dopaminergic neurons in the midbrain and the appearance of neuronal inclusions called Lewy bodies, which contain insoluble α-synuclein, a relatively small protein originally identified in association with synaptic vesicles in the presynaptic nerve terminals. Drugs that replenish dopamine can partly alleviate the motor symptoms, but they do not cure the disease itself. Therefore, there is an urgent need for disease modification in terms of the delay or prevention of neurodegeneration. Recent advances in genetic and biochemical studies have provided unifying conceptual frameworks of the pathogenesis of PD. Particularly, membrane trafficking has aroused special attention as an initiator or enhancer of the neurodegenerative process that leads to PD. Defects in the cellular trafficking pathway result in synaptic dysfunction and the accumulation of misfolded α-synuclein. Likewise, changes in intracellular sorting and degradation profoundly influence the cellular trafficking of misfolded proteins, thereby facilitating the cell-to-cell spreading of hazardous α-synuclein species in a prion-like manner. Here, we will review our current knowledge of the functional roles of membrane trafficking in PD and will discuss how this cellular process could induce or facilitate the functional and pathological alterations in this disease.

26 December 2023 in The FEBS Journal
Verified
Journal Article
Open access
TNTakaaki Nakamura
Takaaki Nakamura
NSNaoto Sugeno
Naoto Sugeno
THTakafumi Hasegawa
Takafumi Hasegawa
KIKensho Ikeda
Kensho Ikeda
SYShun Yoshida
Shun Yoshida
MAMasashi Aoki
Masashi Aoki
α‐Synuclein (αS) is a key molecule in the pathomechanism of Parkinson's disease. Most studies on αS to date have focused on its function in the neuronal cytosol, but its action in the nucleus has also been postulated. Indeed, several lines of evidence indicate that overexpressed αS leads to epigenomic alterations. To clarify the functional role of αS in the nucleus and its pathological significance, HEK293 cells constitutively expressing αS were used to screen for nuclear proteins that interact with αS by nanoscale liquid chromatography/tandem mass spectrometry. Interactome analysis of the 229 identified nuclear proteins revealed that αS interacts with the BRG1‐associated factor (BAF) complex, a family of multi‐subunit chromatin remodelers important for neurodevelopment, and protein arginine methyltransferase 5 (PRMT5). Subsequent transcriptomic analysis also suggested a functional link between αS and the BAF complex. Based on these results, we analyzed the effect of αS overexpression on the BAF complex in neuronally differentiated SH‐SY5Y cells and found that induction of αS disturbed the BAF maturation process, leading to a global increase in symmetric demethylation of histone H4 on arginine 3 (H4R3me2s) via enhanced BAF–PRMT5 interaction. Chromatin immunoprecipitation sequencing confirmed accumulated H4R3me2s methylation near the transcription start site of the neuronal cell adhesion molecule (NRCAM) gene, which has roles during neuronal differentiation. Transcriptional analyses confirmed the negative regulation of NRCAM by αS and PRMT5, which was reconfirmed by multiple datasets in the Gene Expression Omnibus (GEO) database. Taken together, these findings suggest that the enhanced binding of αS to the BAF complex and PRMT5 may cooperatively affect the neuronal differentiation process.

1 August 2005 in Journal of Clinical Neuroscience
Verified
Journal Article
Closed access
THTakafumi Hasegawa
Takafumi Hasegawa
NSNaoto Sugeno
Naoto Sugeno
YSYusei Shiga
Yusei Shiga
ATAtsushi Takeda
Atsushi Takeda
HKHiroshi Karibe
Hiroshi Karibe
YIYasuto Itoyama
Yasuto Itoyama